(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 scientists hunting for new ways to treat type 2 diabetes.
Britain’s vote last year to leave the European Union was disappointing but did not undermine the case for working with a renowned center of science, said Mads Krogsgaard Thomsen, Novo’s chief scientist.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk puts $145m into U.K. research center appeared first on MassDevice.
from MassDevice http://ift.tt/2kKohgw
Cap comentari:
Publica un comentari a l'entrada